Toker expressed pleasure over his new position in a press release and said: “The Turkish pharmaceutical market is going through a transformation in accordance with the world market. Rising demand at a time of global economic slowdown leads to sudden changes in prices and profits, and those who keep pace and make accurate predictions continue to exist in this market.” He added: “At this time, Actavis is strengthening its position in the market as well as in new areas as a result of investment in research and development. Turkey is one of the countries in which Actavis plans to invest to grow its market. Recent regulations in the drug industry in Turkey have increased the need for reliable companies that can cooperate with the government.”
Toker noted Actavis aims to continue organic growth in the country and at the same time strengthen its position. “We will be making investments in domestic production facilities and are interested in purchases in the future. In addition, we will be working to offer higher quality drugs at economical prices for the Turkish people,” he said.